Background:In1999,SaskatchewanHealth authorized pharmacists to initiate exception drug status (EdS)requests,also knownasprior authorization (Pa).Before 1999,onlythose licensedtoprescribe medications were authorizedtoinitiate EdSrequests. apharmacistwho submitsan EdSrequest must obtain apatientdiagnosis fromthe physicianoragent of thephysician; adiagnosis presented by thepatientisinsufficient. oBjEctIvE: to obtain pharmacists'opinionsabout thebenefitsofthe Pa programofthe SaskatchewandrugPlanand to identify factorsassociated with pharmacist-initiatedEdS requests.
What is alreadyknown aboutthissubject
What this studyadds M edicareinCanadaisaf ederal programthathas evolved over nearly40years to provideCanadiansaccesstomedicallyn ecessary physician andh ospitals ervices, includingdrugs administered in hospitals. However, each provincial and territorialg overnmenti ndependently developeda nd continuest o developp rogramst op rovide drug coveragef or some or allo fi ts residentsinthe communityorinnonhospital facilities.The federal government hasalsodeveloped andcontinuestodevelop drug programsf or select groups,including veterans andF irst Nations and Inuitpeoples.However,morethanhalfofall prescriptionsare paid throughprivate insuranceordirectly by individualsorpatients. 1, 2 In 2005,Canadahad 7,778community pharmacies comprising chaina nd banner pharmacies (58.6%), independent pharmacies (21.4%), andpharmaciesinfood andmass merchandisers (20.0%). 3 In 2005 in Saskatchewan, public fundspaidfor 48%ofthe $554 perc apitas pent on prescription drugs, whereasC anadaa sa wholespent $640 percapitaonp rescriptiondrugs,with46% of thee xpenditure paid forw ithp ublicf unds. 4 Thea verage retail pricef or ap rescriptioni n2 005w as $45.66,w hich included dispensing andprofessionalfees. 3 As in othercountries,the final cost to thepatient varied considerably dependingonthe markup anddispensingfee charged.
Over they ears,i ncreasingr eliance on drug therapya nd a tendencytoabandon olderdrugtherapiesfor newer,moreexpensive agents have causedd rugu tilization ratesa nd expenditures forprescriptiondrugs to grow substantially. 1, 5, 6 Drug planshave attemptedt oc ontrol theser isingc osts in av ariety of ways, includinglimitingc overaget oc ertain cohortso fthe population (i.e., low-income families), increasingcopayments, or introducing deductibles. The result has been an ongoings hiftingo fc osts to patients andprivate insurers. 7, 8 In 1973,t he Saskatchewanp rovincialg overnmenti mplemented ac omprehensived rugp lan viaS askatchewanH ealth's Drug Plan andExtendedB enefits( Drug Plan)B ranch. Allc osts, with theexception of asmall copayment, were publicly funded. 7, 9 Today, Saskatchewanresidents arestill coveredbythe provincial drug plan,b ut most beneficiariesm ustm eetanannual, incomebaseddeductible(3.4% of household income)beforereceiving any financialsupport from theg overnment. 9 SinceJ uly2 007, seniors (all Saskatchewan residentsaged65years andolder)pay no more thanCan $15per prescription (1-monthsupply) ford rugs listed on theprovince'sformulary. 10 Utilization trends in Saskatchewan providea ni nteresting picture of drug expendituresi nt he province.I n1 995-1996, 633,333 active beneficiariesi nS askatchewan received5 ,798,090 prescriptionsf or at otal prescription cost of Can$ 157,194,207 (Can $248 perbeneficiary), andthe Drug Plan paid Can $59,492,033 (37.8%)o ft he totalc ost. 9 Teny ears later, in 2005-2006, then umbero fa ctiveb eneficiarie sh ad increasedb yo nly 0.8% to 638,637, whilethe number of prescriptionsincreased 62%t o9 ,364,871 andt otal prescription costsi ncreased by 239% to Can $375,304,926( Can$ 588p er beneficiary);t he SaskatchewanD rugP lanp aidC an $181,288,493 (48.3%)o f thet otal prescription cost,anincreaseo f305%. 9 Therefore, whilet he number of active beneficiariesr emained virtuallyunchanged,the number of prescriptionsper active beneficiary, averagecostper prescription,and perprescriptionproportion paid by theSaskatchewanDrugPlan increased dramatically. Managed care interventionsthathavebeen implemented,suchas prior authorization( PA)i nt he late 1970sa nd therapeuticm aximumallowable cost,which beganwithproton pump inhibitors in July 2004,are attemptsbythe SaskatchewanDrugPlan to control escalatingcosts andtherebyensure itslong-term viability.
Even with restrictivepoliciesand cost shifting, drug utilization ratesc ontinue to rise and, with them, thec osto fp roviding drug coverage. 11 Both public andp rivate drug plansh avee xpanded variousm anagements trategiess ucha sP Ai na na ttempt to stem rising drug expenditureswhile maintainingaccesstoeffective drug therapies. PA limitsthe useofselected drugsbyrequiringadvance approvalfor reimbursementofcertain drugswhenless costly alternativesare available. 12 However, some aspectsofthese strategies can become sourcesofcontentionbetween payers, patients,and health care providersbecause they maybeperceived as limitingaccessto needed drugsb yr equiringa dministrative approvalf or coverage.
Additional administrative tasks areassociated with theseprograms thathealth care professionals areexpected to assume. 13 In Saskatchewan, PA is knowna st h eE xception Drug Status (EDS)p rogram. 14 Forthe patienttoreceive provincial government coverage forrestricted formularydrugs,EDS approvalmustfirst be obtained-a processthatmustbeinitiated by an authorized health care professional (physician,d entist,o ptometrist,n urse practitioner,o rp harmacist).S omep rivate drug plansh avet he sameo r similarrequirements fordrugs in theSaskatchewan EDSprogram. Afew examples of EDSprogram drugsand coverage criteriainclude azithromycin permitted forp atientsi ntolerantt oe rythromycin and/or other antibiotics, insulinl isprop ermitted fort reatmento f patients usingi nsulin pumpso rd ifficult-to-controld iabetes, and pioglitazone hydrochloride( HCl) or rosiglitazonem aleate permitted fortreatment of patients whopreviously received prescriptions formetformin or sulfonylureasand arenot adequatelycontrolledon or areintoleranttometformin or sulfonylureas. 15 When submittinganEDS request, theauthorizedhealth care professional canphone,mail,orfax therequest to Saskatchewan Health;h owever,o nlyt he patienta nd prescribingp hysician receiveconfirmationletters.The pharmacist is notifiedwhenhe or she accesses thep atient profi le viat he Drug Plan's database. Informationr equiredt os ubmit an EDSr equesti ncludes the (1)patient name,( 2) patienthealth services number,( 3) diagnosisr elevantt ou se of drug,a nd (4)p rescribern amea nd phone number. 15 The information required to submit an EDSrequestfor anonapproveddrugincludes( 1) t he diseaseorproblem treated, (2)the list of previoustherapiesand responses, (3)other non-EDS therapiestried andwhy they aren ot appropriate forthe patient, (4)clinicalevidencetosupport thetherapybeing requested,and (5)o utcomest oa ssess effectiveness of ther equested therapy. 15 (Figurefor EDSrequest form. 16 ) In July 2006,t he Drug Plan implemented online adjudication for2drugs (pioglitazone HCland rosiglitazonemaleate)through an electronicstep-therapyprogram.EDS claimsfor these2drugs can be submitted anda djudicated directly throught he online claims transactionsystem. 15 Forthese 2drugs,the online transaction processingsystemchecksthe patient'sdrugprofile andifthe first-line drugs(metformin or sulfonylureas) appearinthe system, thecoverageand approvalletterisautomaticallygenerated forthe patient. 15 Health care professionalsasawhole arenot compensated by the Saskatchewan Drug Plan forEDS requests.H owever,the Medical Services Branch (not theS askatchewan Drug Plan andE xtended Benefits Branch thata dministersthe EDSp rogram), compensates physiciansC an $4 fori nformation requests from health care professionals, includingp harmacists,f or ad iagnosis from the physician to submit an EDSr equest.( written communication, G. Bradley,J anuary2 005).T herefore,i ft he physician writes on theprescription"apply forEDS"but does notprovide therequired diagnosiso nt he written prescription,w hent he pharmacist contactsthe physician to obtain thepatient's diagnosis, thephysician mayclaim aCan $4 feefor thatinformation request. 
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Before 1999,o nlyt hose practitionersl icensedt op rescribe in thep rovincew erea blet oi nitiat eE DS requests.I n 1999, SaskatchewanH ealth expandedt he programt oa llow licensed pharmacistst oa pplyf or EDSo nb ehalfo ft heir patients. Allowing pharmaciststoinitiate theserequests wasseen as away to improvea ccesst op rescriptionm edicationand assist patients in securing allavailable sourcesoffunding fortheir prescription medications. 14 However, theE DS programr equires thep harmacist to obtain thep atient's diagnosisf romt he physician or physician's agentinorder to submit an EDSrequest. 15 Since1999,whenlicensedpharmacists in Saskatchewanwere allowed to initiate EDSr equests,r esearchh as notb een conducted on howthe policy affectscommunity pharmacy practice. As noted in previous studiesonPAorstep-therapyprograms, [17] [18] [19] [20] oftenthe drug costsand savingsare evaluated whilethe perspective of thep roviders (e.g., pharmacists) aren ot addressed. This paperr eports on thee xperiences ando pinionso fc ommunity pharmacy managers,o rt heir delegates,a nd theirp harmacies with regard to Saskatchewan Health's EDSp rogram andi ts effect on communityp harmacy. Ethics approvalwas appliedf or andr eceivedfromthe University of Saskatchewan's Behavioural Research Ethics Boardbeforethissurveywas conducted.
Methods
StudySample andDesign
Ac ensuss urveyo fc ommunity pharmacy managers in Saskatchewanw as conducted in the fall of 2004.P harmacy managers werechosenoverindividual pharmaciststoreducethe potentialofhaving2ormorepharmacists'perspectivesrepresented from thesamepharmacy. In September 2004,wereceivedan up-to-date list of all346 communitypharmaciesinthe province from theS askatchewanC ollegeo fP harmacists,t he regulatory bodyf or pharmacistsi nS askatchewan. In identifyingd istinct communityp ractices,w er educed then umbert o3 33 as ar esult of pharmacy closure( 1) andofpharmaciesoperatingassatellites in remote communitiest hatd id noth aveap harmacym anager and/or pharmacist specifically forthe satellite location (12) .
Followingthe Tailored Design Method forthe conductofsurveys,wesentaprior notice letter in October 2004 to community pharmacy managers whow erel icensedp harmacists. 21 In the letter,p rospective survey respondentsw erea sked to complete theq uestionnairew heni ta rrived or to designateam ember of theirstaff whom they thought wasmost qualified to answer.This presurveyletterwas followed 1weeklater by thequestionnaire, whichi ncludedac over letter andp restampedr eturne nvelope. Ar eminderp ostcardt on onrespondersw as sent 2w eeks later. Afinal mailing wassent2weeks afterthe reminderpostcardt o nonrespondents andincluded anothercopyofthe questionnaire, acover letter, andap restampedreturnenvelope. Thestudy collectionperiodclosed4weeks afterthe finalmailing.
Once thestudy period concluded,weperformed anonrespondent survey.Ao ne-timeq uestionnairea nd coverl etter, along with aprestampedreturnenvelope, were sent to nonrespondents in an attemptto estimate potentialbiasesinthe s ample.
Survey Instrument
Drawing on ar eviewo ft he relevant literature, 6,22-44 we constructed theq uestionnairet oa ddress as erieso ft opicsr elating to PA andthe EDSp rogram in Saskatchewan. These topic areas included potentials takeholder benefits from aP Ap rogram,t he volume of EDSrequestsreceivedbythe pharmacy,factors influencing thedecisiontoinitiatearequest,and theappropriateness of procedures used to submit ar equest.I nformation wasa lso gathered with regard to thearea, location, andtypeofpharmacy; then umbero fp harmacists andp harmacyt echniciansi nt he respondent's pharmacy;t he proximityo ft he prescribingp hysicians; prescription volume;and hoursthe dispensary waso pen. Demographics were also collected on respondents'g ender, age, position,and yearsintheir currentposition.
Aftert he questionnairew as devel oped,c ontent andf ormat wereevaluated usingapretestinvolving 5community pharmacy managers.Inthe pretest, managers wereasked to providef eedback on thed esigno ft he questionnaire, itsr elevance,a nd the flow of individual questionsa nd betweens ections.C omments werealsoobtainedfromSaskatchewa nDrugPlan representatives andane xpertinq uestionnaired esignf romthe Department of Managementa nd Marketing, Collegeo fC ommerce,U niversity of Saskatchewan.
The finali nstrumentc ontained 5p ages of questionsw ith an averageo f8q uestions on each page (a copy of thei nstrument is availablef romt he correspondinga uthor).I tems were measured primarilywith5-point and7 -point Likert-typescales. Respondentsw erealsoasked to complete ad emographicsp age, ands pace wasp rovidedf or additional comments,w hich are reported elsewhere. 46 
Data Analysis
Descriptives tatisticsw erec alculated fora ll items. Comparative analysisw as carriedo ut usingt he Mann-Whitney U test and Kruskal-WallisOne-Way AnalysisofVariance.Nonparametric tests were selected over parametric testsbecause of theprimarily ordin al nature of thed ata. Forp ost hoca nalysis, theB onferronit estw as used to identify statistically significantdifferences betweenrespondentsw henf actors werec ompared.A ll statisticala nalysesw ere conducted usingSPSS13.0for Windows( Chicago, IL).
Results
StudyPopulation
At otal of 279q uestionnaires werer eturned. Afterd atac ollection concluded, 4a dditionalq uestionnaires were received but were notincludedinthe analysis.Ofthe eligible questionnaires received, 275w erep roperlyc ompleted,f or af inal response rate of 82.6%( 275/333). Of the5 0n onrespondentq uestionnaires thatweremailed afterthe studyperiod, 15 were returned
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(30%). Therewerenostatisticallysignificantdifferencesbetween respondents of theo riginals urvey andr espondentso fthe nonrespondentsurveyonany common measures, includinggender, respondents'p osition, proximityt op rescriber, communitys ize, averagen umbero fp rescriptions filled perw eek, andh ours the pharmacy wasopen( data notpresented).
Of the2 73 respondentsr eportingt heir gender,n earlyt wo thirds were male (64.2%). Almost half (49.1%) identified themselvesa st he manager, andm oret hano ne thirdo fr espondents identified themselves as theowner (36.4%). Thereported average prescription volume perw eek( 745, Table1 )i sl ower thant he national averageo f833. 5 The averagen umbero fp harmacists (2.8)a nd pharmacy technicians( 2.4) perl ocationw erea lso belowthe national averageof3.5 and4 .3,respectively. 5 An averageo f3 6r estricted/nonformularyp rescriptions werereceivedper week whichrepresented5%ofthe reported prescription volume (Table 1 ).C ompared with 1999,w hen pharmacies didn ot submit anyE DS requests,w ef ound that respondents reported thatt heir pharmacies submitted 79% of all requests,w ith2 9% of theseE DS requests submitted by thep harmacya tt he requesto f thep rescribing physician.T herefore, communityp harmaciess ubmit an average of about1 7E DS requests perw eeko ut of the5 9% of 22 of ther estricted andn onformularyp rescriptions received by thep harmacya nd submitted by either thep harmacyo r physician.Circumstances such as thepatient notmeetingthe EDSe xception criteria (e.g., noth avingt ried previous drug therapiesr equiredf or approvalo rn o th avingt he testsd one [sucha sc ulture ands ensitivity fors omea ntibiotics]) makes submissiono fsomerequestsunnecessary.
Stakeholders andthe EDSProgram
Am ajorityo fr espondents( 63%) agreedo rs tronglya greed thatt he EDSp rogram benefited patients by expandingt he number of prescription medications coveredb yt he provincial drug plan ( Table 2 ).Am ajority( 64%) also agreedo r strongly agreedthatthe provincial drug plan benefited from theEDS programb yallowingcostly medicationst obea vailable in am orecontrolledmanner.
Fewerr espondentsa greedo rs tronglya greedt hatt he EDS programb enefited theh ealth care system (39%)b yp romoting more appropriate utilization of drugs, while3 7% of community pharmacy managers agreedorstronglyagreedthatthe EDS programb enefited physiciansb yprovidingt hemw ithm ore drug therapyc hoices fort heir patients.O nly1 5% of respondentsagreedo rstronglyagreedthatthe EDSp rogram benefited pharmacistsbyproviding them with an opportunitytobemore actively involved in securing the most appropriate drug therapy fortheir patients.
FactorsAssociatedWithaPharmacist-InitiatedEDS Request
In assessingt he importance of factorst hatm ight influence whetherapharmacistinitiated an EDSrequestonbehalfo fthe patient, 74%o fr espondents indicated thea bility of thep atient to payf or thep rescriptionw as an importanto rv eryimportant factor (Table 3) .Other factorsseen as importanto rv eryimportant in initiatinga nE DS requesti ncludedt he ability to obtain allt he information needed to make ther equest( 77%) andt he pharmacist's ability to contactthe prescribingp hysician (70%). Respondents whow erei nt he samel ocation( co-located in the sameb uilding) as thep rescribing physician werel essl ikelyt o consider proximitya saf actorc omparedw itht hose whow ere removedgeographically(χ 2 =18.41; P <0.01, data notshown in tables). Thetimerequiredtosubmit an EDSrequest wasseenas thel east importantf actor, with only 39%indicatingthisf actor as importantorveryimportant.
Experience With EDSRequests
Seventy-nine percento fr espondentsa greedo rs trongly agreedt hatp harmacists in theirp harmacyb elieve that initiatinga nE DS requesti sa ni mportant servicef or their patients,a nd 75%a greedo rs tronglya greedt hatt heyh ad adequateinformation on theadministrative nature of theEDS program( Table4 ).
With regard to the1 999 policy change allowingpharmacists to initiate EDSr equests, 71%a greedo rs tronglya greedthatthe change in policy hadb een beneficial to patientc are. However, most (96%)a greedt hatt he change hads ignificantly increased 
Discussion
As prescription drug use ande xpendituresc ontinue to increase, 11 variousinterventions such as PA areimplementedto manage theuse of pharmaceuticals-targetingdrugs forwhich therea re less costly alternatives available. 12 The principal stakeholders in PA programs arepatients, pharmacists, physicians, drug plans, anda dministrators. 28, 34, 36, 39, 41 Traditionally, physiciansh aveb eent he health care professionalst hata pply forP Acoveragef or apatient,b ut some drug planssuchasthe Saskatchewan Drug Plan have authorized pharmacistst oa lso initiate PA requests.
Other researchersh avee stablishedt he financial benefits of PA or step-therapy programs by identifyingar eduction in directd rugc osts. [18] [19] [20] Throught he examinationo fo ne aspect of thehumanistic-service outcomes, thepresent studyexpands ourunderstanding of PA programs.S pecifically, we examined some of thef actors associated with theu ptakeo fap olicy designed to allowp harmacists to applyf or PA on behalf of theirp atientsa nd thep erceptions of communityp harmacists associated with this policy.
Whilewedid notmeasure theproportionofpharmacystaff time required forEDS submissions,the administrative burden is nots mall sincep reparing ands ubmittingE DS requests requires more time thans implyf i lling thep rescription. Furthermore, pharmacistsare notcompensated financiallyfor thes ervice.I ti sn ot surprising thatm ostr espondents indicated thatt he currentE DS policy wasb eneficialt op atients andp recribersb ut viewed thep olicya sa na dditionalb urden forpharmacists.
Givent he additional workloadd emands thatt he EDSp rogram places on pharmacists, it wasn ot unexpected thatt he respondents believed thatp harmacists benefited thel east from theE DS program. However, it wass omewhat surprising that pharmacistsr eported thatt he time required to providet he service wasthe leasti mportant factor when deciding to initiate an EDSr equest.F actors such as thea bility to obtain ther equired information andt he ability to contactt he prescriberw ereo f greaterconcern.Thissuggestsaneedtoimprove communication andt he role definition forb otht he pharmacist andt he physician.Effective communicationand collaborationbetween physiciansa nd pharmacistsw ill likelyi mprove humanistic-service outcomes forp atients, includingr eduction in thetimed elaysin obtainingmedications. 18 Respondentsi nt he samel ocationa sp rescribing physicians werel esslikelyt obeconcernedwiththeir ability to contact the physician.C o-locationsa nd greatero pportunity forf ace-to-face interactiona llowst he pharmacist(s)t oe stablish good working relationshipsw ithp rescribers.G ood workingr elationships,i n turn,w ould be expected to supportg reater accessibility when initiatinganEDS request.
The ability of thep atient to payw as also ak ey factor in pharmacist decisionst os ubmit requests forE DS coverage. If a patientisunabletopay thecost sharefor themedication, even if approvedvia EDS, it is notproductivefor thepharmacisttoapply forEDS coverage. Although it appears thatr espondentsd on ot necessarily mindt he time required to submit an EDSr equest, they are concernedabout theirability to obtain theinformation necessary forinitiatinganE DS request. The fact thatp harmacists aren ot likely to have thei nformation required fora nE DS requesti st roubling.T he idea behinda uthorizingp harmacistst oa pplyf or EDSo nb ehalfo fp atientsw as to increase timely access to prescription drugsf or patients.H owever, whent he pharmacist does noth avet he necessaryi nformation to make thatrequest in atimelymanner,the processmay actually be lengthened. 36 An evolving partialsolutionmay be foundinthe Saskatchewan Pharmaceutical InformationProgram (PIP). PIPisdesignedtolink communityp hysicians, pharmacies,and hospitals, providingconfidentials hareda ccesst op atient medicationh istories. 46 However, whileP IP mayh elpalleviate some of thecurrentbarrierst op harmacist review of thec ompletem edicationh istory forap atient,i t does notprovide thepharmacistwithaccesstoother medicalinfor- 15 Whilet hisi sap ositives tepi na ddressing some of theissuesaroundthe administrative workloadinherent in PA programs,t he online adjudication system currentlyo nly includes 2drugs.
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Fundingisclearly needed to institutemeasuresthatexpedite andstreamlinethe manner in whichpharmacists applyfor EDS, such as themovetoonlineadjudication(smartedit).Inaddition, considerationm ustb egiven to paying pharmacistsa na ppropriate feefor theservice they provide. F inancial compensation is importantb ecause it givest angibler ecognition of the pharmacist's professionalr oleind eliveringa ppropriate drug therapyw hile also providinga ni ncentive forp harmacists andp harmaciest op rovide as ervice thatc learly benefits patients in improved access to car eand physiciansinreduced administrative workload.
Limitations
First, this is ap reliminarys tudy of pharmacist perceptions thatd id noti nvolve collectingi nformation thatm ight be used to improvep rocesses such as thea veraget imer equiredo f pharmacy staffper EDSsubmission andthe proportion of total pharmacy time andp ayroll consumed by theE DS process. Second,the resultsobtainedfromthe survey pertainonlytothe province of Saskatchewan,C anada, andm ay notb ea pplicable to otherjurisdictions.Third,since this survey wasaddressed to communityp harmacymanagers, ther espondentst endedt ob e oldera nd were oftent he ownerso ft he pharmacies.T herefore, theo pinionsrecordedinthissurveymay notrepresent practicingpharmacists in general.
Conclusions
Pharmacistsrespondingtothe survey viewed theEDS programas beingbeneficial to patients butw erec oncerned with thea dministrativeb urden. Concerns with theE DS programf ocus on the administrative nature of thep rogram,i ncluding thei nefficient manner in whichp harmacists arer equired to applyf or EDS duet ol acko fa ccess to required patienti nformation,i ncluding diagnosisa nd complete prescription drug history. To maintain pharmacists' supportf or this managedc arei ntervention,i tw ill be necessaryt or educet he administrative workload by providingaccess to required information andimplementingsmart edits thats can pharmac yc laimsh istory f or evidence of pr ioru se of first-line drug therapy. Furtherresearchisneededt ocapture the perceptionsa nd experienceso fa ll stakeholders of theE DS program,includingpharmacists,physicians, patients,and drug plan personnel, to help assess humanistic-service outcomes of this managedcareintervention.
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